| Active substance | dapagliflozin |
| Holder | AstraZeneca NV/SA |
| Status | closed |
| Indication | Treatment of chronic kidney disease |
| Public documents | Approbation |
| Approbation Amendment | |
| Information for the patient | |
| Informed consent | |
| Last update | 02/12/2022 |
Forxiga®
Last updated on